Anti-Diabetes Drugs - Cambodia

Cambodia

In Cambodia, the Anti-Diabetes Drugs market is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$22.13m by the year 2024.
Moreover, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 7.65%, resulting in a market volume of US$31.99m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market, with an estimated revenue of US$37,840.00m in 2024.
This indicates the dominant position of the United States in this market.
The demand for anti-diabetes drugs in Cambodia is on the rise due to the increasing prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Cambodia has been experiencing steady growth over the past few years.

Customer preferences: Cambodia has a high prevalence of diabetes, with an estimated 10% of the population suffering from the disease. This has led to an increased demand for anti-diabetes drugs in the country. However, due to the relatively low income levels in Cambodia, customers tend to prefer cheaper generic drugs over branded ones.

Trends in the market: The market for anti-diabetes drugs in Cambodia is dominated by metformin, which is the first-line drug for the treatment of type 2 diabetes. Other drugs such as sulfonylureas and DPP-4 inhibitors are also gaining popularity in the country. In recent years, there has been a trend towards combination therapies, where patients are prescribed a combination of different anti-diabetes drugs to better manage their condition.

Local special circumstances: One of the unique challenges in the Cambodian market is the lack of regulation and enforcement of intellectual property rights. This has led to a proliferation of counterfeit drugs in the market, which can be a major safety concern for patients. In addition, the distribution network for drugs in Cambodia is highly fragmented, with a large number of small pharmacies and drug stores operating in the country.

Underlying macroeconomic factors: Cambodia has been experiencing strong economic growth in recent years, which has led to an increase in healthcare spending. However, the country still faces significant challenges in terms of healthcare infrastructure and resources. The government has been investing in healthcare infrastructure and training of healthcare professionals, which is expected to improve access to healthcare services in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.